Sutimlimab Cad denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sutimlimab cad are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Limits Sutimlimab Quantity — and Why You Can Appeal

Sutimlimab is an intravenous complement inhibitor approved for adults with cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia. BCBS quantity-limit denials for sutimlimab are common because the drug is administered by weight-based infusion on a specific schedule, and plans routinely cap the number of vials dispensed per fill or per period. When the authorized quantity falls short of what your prescriber ordered to complete a full infusion cycle, the claim is partially or fully denied.

## Why This Denial Is Appealable

Quantity limits must be clinically justified. If the limit prevents delivery of the dose documented in the FDA-approved prescribing information for your actual body weight, the restriction is medically inappropriate. The plan is required to evaluate your individual clinical circumstances — not apply a one-size limit without exception.

Federal rules give you strong appeal rights: - ACA §2719 / ERISA §503 require a full-and-fair internal review. You typically have 180 days from the denial notice to file. - External review is available after exhausting internal appeal (or after a deemed exhaustion). The external-review window is generally up to four months from final internal denial. An independent review organization (IRO) then decides. - Expedited review (72-hour decision) is available if the standard timeline would seriously jeopardize your health.

## What to Gather

• Diagnosis confirmation: pathology or lab records confirming CAD; specialist diagnosis letter.
• Weight documentation: current body weight from the chart, used to calculate the correct infusion volume per the prescribing label.
• Prescriber medical-necessity letter: your physician should state the quantity ordered, cite the FDA-approved prescribing information as the basis, and explain that the authorized quantity is insufficient to complete one full weight-appropriate infusion.
• Infusion records: prior administration logs showing the volume actually required.
• Denial letter: note the exact quantity authorized versus ordered — this is your central argument.

## Criteria-Mapping Structure

Copy every requirement from BCBS's published coverage/medical policy for sutimlimab (request it by name or policy number from the plan). For each requirement, provide the matching chart fact:

| Policy Requirement | Supporting Documentation | |---|---| | Diagnosis of CAD confirmed by specified criteria | Specialist letter + lab confirmation | | Weight-based dosing per FDA label | Current body weight from chart + label excerpt | | Quantity per infusion cycle = [per label for your weight] | Prescriber calculation letter |

Your appeal letter should open by stating the approved quantity, then demonstrate — line by line — that the ordered quantity exactly matches the FDA-approved label for your documented weight. Attach the relevant pages of the prescribing information. If BCBS denies again, request external review immediately.